Published in Anal Biochem on July 01, 2004
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett (2010) 1.23
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia (2014) 1.17
A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res (2013) 1.09
A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol (2014) 1.08
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. ACS Med Chem Lett (2013) 1.05
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors. Anticancer Agents Med Chem (2008) 0.97
Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One (2012) 0.95
Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene (2015) 0.92
Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem (2010) 0.90
Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb) (2009) 0.85
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones. Bioorg Med Chem (2013) 0.83
Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medchemcomm (2013) 0.82
Binding modes of peptidomimetics designed to inhibit STAT3. PLoS One (2012) 0.81
Intranuclear crosstalk between extracellular regulated kinase1/2 and signal transducer and activator of transcription 3 regulates JEG-3 choriocarcinoma cell invasion and proliferation. ScientificWorldJournal (2013) 0.81
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer (2014) 0.80
Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins. PLoS One (2013) 0.77
Measurement of dissociation rate of biomolecular complexes using CE. Electrophoresis (2009) 0.76
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ChemMedChem (2016) 0.75
Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget (2016) 0.75
Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. J Mol Model (2014) 0.75
Identification of novel small molecules that inhibit STAT3-dependent transcription and function. PLoS One (2017) 0.75
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol (2011) 1.49
Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol (2006) 1.35
Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem (2008) 1.34
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol (2012) 1.16
FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood (2012) 1.08
A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem (2009) 1.04
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. Chembiochem (2012) 1.02
Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem (2007) 1.01
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem (2008) 1.00
Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions. Traffic (2005) 0.96
A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization. Anal Biochem (2008) 0.94
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem (2009) 0.93
p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Cell Cycle (2012) 0.89
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg Med Chem Lett (2009) 0.87
The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Mol Cancer Ther (2010) 0.81
A scaffold-tree-merging strategy for prospective bioactivity annotation of gamma-pyrones. Angew Chem Int Ed Engl (2010) 0.81
Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivatives. ACS Chem Biol (2011) 0.79
Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a. Angew Chem Int Ed Engl (2015) 0.79
v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77
PYRROC: the first functionalized cycloalkyne that facilitates isomer-free generation of organic molecules by SPAAC. Org Biomol Chem (2015) 0.77
A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1. Methods Mol Biol (2012) 0.76
Oral disinfectants inhibit protein-protein interactions mediated by the anti-apoptotic protein Bcl-xL and induce apoptosis in human oral tumor cells. Angew Chem Int Ed Engl (2013) 0.75
Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptors. J Mol Recognit (2010) 0.75
Synthesis and biochemical evaluation of highly enantiomerically pure (R,R)- and (S,S)-alexidine. Bioorg Med Chem (2013) 0.75
Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1. Bioorg Med Chem Lett (2011) 0.75
The natural product betulinic acid inhibits C/EBP family transcription factors. Chembiochem (2011) 0.75